3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Non-Small-Cell Lung
104
Lung Neoplasms
44
Breast Neoplasms
41
Triple Negative Breast Neoplasms
33
Ovarian Neoplasms
29
Small Cell Lung Carcinoma
25
Squamous Cell Carcinoma of Head and Neck
24
Fallopian Tube Neoplasms
18
Neoplasms
17
Endometrial Neoplasms
17
Uterine Cervical Neoplasms
13
Neoplasm Metastasis
13
Head and Neck Neoplasms
13
Esophageal Squamous Cell Carcinoma
12
Prostatic Neoplasms
10
Parkinson Disease 4, Autosomal Dominant Lewy Body
10
Esophageal Neoplasms
10
Colorectal Neoplasms
10
Carcinoma, Squamous Cell
9
Recurrence
8
Carcinoma, Transitional Cell
8
Oropharyngeal Neoplasms
7
Neuroblastoma
6
Carcinoma, Ovarian Epithelial
6
Urinary Bladder Neoplasms
5
Mesothelioma
5
Lymphoma, Large B-Cell, Diffuse
5
Adenocarcinoma of Lung
5
Stomach Neoplasms
4
Pathologic Complete Response
4
Interventions
enzalutamide
4
Docetaxel
2
pembrolizumab
1
olaparib
1
lenvatinib
1
inavolisib
1
belzutifan
1
abiraterone
1
Prednisone
1
PF06821497
1
Lutetium-177
1
Lutetium
1
Gonadotropin-Releasing Hormone
1
Etoposide
1
Dexamethasone
1
Carboplatin
1
Abiraterone Acetate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Metastatic Castration-Resistant Prostate Cancer
×
Carboplatin
×
Clear all
NCT02861573
2026-02-17
KEYNOTE-365
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
1,200 enrolled